Carroll Financial Associates Inc. lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 43.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,545 shares of the biopharmaceutical company’s stock after selling 1,964 shares during the quarter. Carroll Financial Associates Inc.’s holdings in Gilead Sciences were worth $182,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in GILD. BlackRock Inc. raised its position in Gilead Sciences by 1.9% in the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after purchasing an additional 1,937,031 shares during the period. Vanguard Group Inc. raised its position in Gilead Sciences by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares during the period. FMR LLC raised its position in Gilead Sciences by 1.1% in the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after purchasing an additional 258,005 shares during the period. Northern Trust Corp raised its position in Gilead Sciences by 0.7% in the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after purchasing an additional 116,780 shares during the period. Finally, Franklin Resources Inc. raised its position in Gilead Sciences by 1.0% in the 2nd quarter. Franklin Resources Inc. now owns 14,516,058 shares of the biopharmaceutical company’s stock worth $1,027,436,000 after purchasing an additional 136,884 shares during the period. Institutional investors and hedge funds own 75.71% of the company’s stock.
A number of analysts recently weighed in on GILD shares. JPMorgan Chase & Co. set a $85.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Credit Suisse Group restated a “buy” rating and issued a $82.00 target price on shares of Gilead Sciences in a research note on Thursday, December 7th. Zacks Investment Research downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. ValuEngine upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Finally, Argus downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and upped their target price for the stock from $73.25 to $73.77 in a research note on Monday, November 13th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $87.04.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $80.94 on Wednesday. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $89.54. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.48 and a current ratio of 3.55. The company has a market cap of $105,415.91, a P/E ratio of 9.45, a P/E/G ratio of -1.85 and a beta of 1.22.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. During the same quarter in the prior year, the company posted $2.70 earnings per share. Gilead Sciences’s revenue for the quarter was down 18.7% compared to the same quarter last year. equities analysts forecast that Gilead Sciences, Inc. will post 6.24 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be given a dividend of $0.57 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a yield of 2.82%. Gilead Sciences’s dividend payout ratio is presently 59.77%.
ILLEGAL ACTIVITY NOTICE: This piece was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.com-unik.info/2018/02/21/gilead-sciences-inc-gild-shares-sold-by-carroll-financial-associates-inc.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.